Speake Lab

The Speake Lab works to advance clinical research in type 1 diabetes (T1D) and other immune-mediated diseases using innovative analytical approaches that aim to improve understanding of disease progression, treatment responses, and immune function.

We focus on development and utilization of rigorous analytical methods to identify immune and metabolic features associated with clinical outcomes. Our work in extending the quantitative response (QR) trial outcome is advancing T1D clinical trial design and definition of response to therapy. The team also uses short-term interventions with mechanistic outcome measures to better understand how therapies affect the immune system.

In collaboration with Sandra Lord, MD, and Megan Smithmyer, PhD, the Speake Lab oversees BRI’s biorepositories. The team works closely with academic researchers, biotechnology companies, and pharmaceutical partners around the world while managing BRI’s Clinical Core Lab, which processes and maintains hundreds of thousands of research samples that support clinical and translational research.